Mesothelioma Clinical Trials Overview > Mesothelioma Clinical Trial List
Immunotoxin Therapy, Pemetrexed, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed by Surgery
| Conditions: | Malignant Mesothelioma |
| Start Date: | June 1, 2007 |
| Phase: | Phase I |
| Status: | Recruiting |
| NCT ID: | NCT00575770 |
| Study Type: | Interventional |
| Intervention: | Biological: SS1(dsFv)-PE38 immunotoxin|Drug: cisplatin|Drug: pemetrexed disodium|Other: immunoenzyme technique|Other: immunohistochemistry staining method|Other: pharmacological study|Procedure: quality-of-life assessment |
| Study Design: | Allocation: Non-Randomized|Control: Active Control|Masking: Open Label|Primary Purpose: Treatment |
| Results: | No Results Available |
| Sponsors: | National Cancer Institute (NCI) |
| Ages: | Adult|Senior |
| Enrollment: | 24 |
| Funded By: | NIH |
| First Received: | December 15, 2007 |
| End Date: | |
| Last Updated: | November 26, 2009 |
| Last Verified: | March 1, 2008 |
Mesothelioma
Lawsuit Evaluation
Lawsuit Evaluation
